Fwd: Switching Off Inflammatory Protein IL-11 Extends Lifespan and Reduces Age-Related Diseases in Mice
Sent from my iPad Begin forwarded message:
From: Inside Precision Medicine
Date: July 19, 2024 at 12:15:22 PM GMT-3 To: mxh5000@gmail.com Subject: Switching Off Inflammatory Protein IL-11 Extends Lifespan and Reduces Age-Related Diseases in Mice Reply-To: Inside Precision Medicine View email in a browser | Forward to a Colleague
Inside Precision Medicine
Inside Precision MedicineTODAY July 19, 2024
Switching Off Inflammatory Protein IL-11 Extends Lifespan and Reduces Age-Related Diseases in Mice In a new study, scientists at the Medical Research Council Laboratory of Medical Sciences and Imperial College London have discovered that "switching off" a protein called IL-11 can significantly extend the healthy lifespan of mice by nearly 25 percent. + MORE
AI-Human Interaction Could Aid Pancreatic Cancer Diagnosis Artificial intelligence could help distinguish cancerous and non-cancerous lesions in the pancreas and may be particularly helpful for novice endoscopists, trial findings suggest. + MORE
Roche Oral GLP-1 Agonist Scores in Early Trial Roche has announced positive interim results from an ongoing Phase I trial for its oral small molecule GLP-1 receptor agonist which would enter a highly competitive market. + MORE
Million Veteran Program Bridges Diversity Gap in Genome-Wide Association Studies Researchers have now published the results of a GWAS using samples from the United States Department of Veterans Affairs (VA) Million Veteran Program (MVP) that includes more than 635,000 samples--29 percent of them from individuals of color, i.e. those who do not self-identify as non-Hispanic White. + MORE
SPONSORED Companion Diagnostics (CDx)--A Central Laboratory Perspective Strong technical, regulatory, and operational delivery capabilities required for CDx development. + MORE
DIGITAL EXCLUSIVE: Building a Bridge Between Rare Disease Patients and the Technologies that Could Help Them
Julia Vitarello is on a personal mission to open up access to individualized therapies for people with rare diseases, starting in the U.K. with the government-backed Rare Therapies Launch Pad. + MORE
About Precision Medicine
Subscribe
Advertising
Stay Connected:
Inside Precision Medicine Mary Ann Liebert, Inc., publishers 140 Huguenot Street, New Rochelle, NY 10801, USA
MANAGE e-SUBSCRIPTIONS Update All Email Preferences | View IPM Privacy Policy
You have received this email at mxh5000@gmail.com.
Unsubscribe
participants (1)
-
Marta Hallak